Novocure LTD Form 4 insider transactions

NovoCure Ltd. reports that Chief Human Resources Officer Michal Nath Puri acquired ordinary shares through the company's Employee Stock Purchase Plan.

NovoCure Ltd. reports that CEO Frank X. Leonard acquired 1,905 ordinary shares through the company's Employee Stock Purchase Plan.

NovoCure CEO Frank Leonard sold 34,273 shares to satisfy tax withholding obligations related to the vesting of restricted stock units.

Director Gabriel Leung was granted 11,610 restricted stock units and 16,999 stock options by NovoCure Ltd.

Director Kristin Stafford was granted 11,610 restricted stock units and 16,999 stock options as part of annual compensation.

Director Allyson J. Ocean was granted 11,610 restricted stock units and 16,999 stock options by NovoCure Ltd.

Director Timothy J. Scannell acquired 11,610 restricted stock units and 16,999 stock options as part of an annual equity grant.

Director Jeryl L. Hilleman was granted 11,610 restricted stock units and 16,999 stock options as part of annual compensation.

NovoCure Director David Hung was granted 11,610 restricted stock units and 16,999 stock options as part of annual compensation.

NovoCure director Martin J. Madden was granted 11,610 restricted stock units and 16,999 stock options on June 3, 2026.

Director Vernon W. Anthony was granted 11,610 restricted stock units and 16,999 stock options as part of standard compensation.

NovoCure Ltd. director Gabriel Leung has sold 2,945 ordinary shares to cover tax withholding obligations upon the vesting of Restricted Stock Units.

Kristin Stafford, a Director at NovoCure Ltd, reported a transaction involving the sale of 2,945 ordinary shares on June 2, 2026, to cover tax withholding obligations.

NovoCure Ltd. reports a transaction where Director Allyson J. Ocean sold 2,945 ordinary shares to cover tax withholding obligations upon the vesting of Restricted Stock Units.

NovoCure Ltd. Director Timothy J. Scannell sold 2,945 ordinary shares to cover tax withholding obligations upon the vesting of Restricted Stock Units.

NovoCure Director Jeryl L. Hilleman sold 2,945 ordinary shares to cover tax withholding obligations upon the vesting of Restricted Stock Units.

NovoCure Ltd. Director Vernon W. Anthony reported a sale of 2,945 ordinary shares to cover tax withholding obligations upon the vesting of Restricted Stock Units.

NovoCure Ltd. reports a transaction where Director David Hung sold 2,945 ordinary shares to cover tax withholding obligations upon the vesting of Restricted Stock Units.

NovoCure Ltd. Director Anthony Vernon acquired 21,500 ordinary shares through the exercise of stock options.

NovoCure's former Chief Medical Officer, Nicolas Leupin, sold 1,100 ordinary shares to cover tax withholding obligations related to vested Restricted Stock Units.

NovoCure's former CEO, Ashley Cordova, disposed of 17,638 ordinary shares to cover tax withholding obligations related to Restricted Stock Unit vesting.

NovoCure's General Counsel, Ben Arye Barak, was granted 50,125 restricted share units and 73,340 stock options as part of his compensation package.

NovoCure's Chief Medical and Innovation Officer, Uri Weinberg, reported the acquisition of restricted share units and stock options, alongside a tax-mandated sale of shares.

NovoCure's Chief Financial Officer, Christoph Brackmann, reported the acquisition of restricted share units and stock options, alongside a non-discretionary sale of shares to cover tax obligations.

NovoCure CEO Frank X. Leonard reported the grant of 150,000 restricted share units and 216,388 stock options, alongside a mandatory 'sell to cover' transaction for tax obligations.

NovoCure's Chief Operating Officer, Mukund Paravasthu, reported the vesting of restricted share units and stock option grants, alongside non-discretionary share sales to cover tax obligations.

NovoCure's Executive Chairman, William F. Doyle, reported significant equity transactions including RSU vesting, option grants, and tax-related share sales.

NovoCure's Chief Medical and Innovation Officer, Uri Weinberg, reported routine share acquisitions from RSU vesting and sales to cover tax obligations.

NovoCure's Chief Operating Officer, Mukund Paravasthu, reported a non-discretionary disposition of 2,133 ordinary shares to cover tax obligations related to RSU vesting.

NovoCure's Chief Financial Officer, Christoph Brackmann, disposed of 7,033 ordinary shares to cover tax withholding obligations related to Restricted Stock Unit vesting.